Condition: Neoplasms, Colon · Sponsor: GlaxoSmithKline
The main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for "capecitabine + oxaliplatin") to check if using these two together works better than using just CAPEOX by itself. This treatment is given before any surgery takes place; a method referred to as "neoadjuvant therapy." . The aim is to see if this new approach can show early signs of effectiveness in treating participants with a specific type of colon cancer known as mismatch repair proficient/ microsatellite stable (MMRp/MSS), where the cells have normal repair systems and stable DNA sequences. This study will also look at specific signs in the blood and tumor to see if they can help predict how well the treatment is working. This could help better understand how dostarlimab contributes to the response of the disease to treatment.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Aalst, Belgium | Recruiting |
| GSK Investigational Site | Bonheiden, Belgium | Recruiting |
| GSK Investigational Site | Brussels, Belgium | Recruiting |
| GSK Investigational Site | Brussels, Belgium | Recruiting |
| GSK Investigational Site | Ghent, Belgium | Recruiting |
| GSK Investigational Site | Leuven, Belgium | Recruiting |
| GSK Investigational Site | Liège, Belgium | Recruiting |
| GSK Investigational Site | Liège, Belgium | Recruiting |
| GSK Investigational Site | Ostend, Belgium | Recruiting |
| GSK Investigational Site | Roeselare, Belgium | Recruiting |
| GSK Investigational Site | Turnhout, Belgium | Recruiting |
| GSK Investigational Site | Milan, Italy | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06567782